Ten healthy adult volunteers were treated with Cellectra device and were asked to report the level of discomfort they experienced immediately after electroporation and at various times thereafter. The procedure was generally well tolerated.
Joseph Kim, president and CEO of VGX Pharmaceuticals, said: “This is just the first step in our aggressive strategy to develop a potent and prolific DNA-based drug and vaccine development platform.”